ArticleMolecular medicine reports2018
Protection of Luteolin-7-O-glucoside against apoptosis induced by hypoxia/reoxygenation through the MAPK pathways in H9c2 cells.
Article in Molecular medicine reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Recent Trends in the Application of Chromatographic Techniques in the Analysis of Luteolin and Its Derivatives.Biomolecules · 2019Pooled it
- Protective effects and mechanisms of cynaroside on renal fibrosis in mice with unilateral ureteral obstruction.Redox report : communications in free radical research · 2025Article
- LC-HRMS/MS-Guided Profiling and Biological Evaluation ofMolecules (Basel, Switzerland) · 2025Article
- Curcumin Ameliorates Cisplatin-Induced Cardiovascular Injuries by Upregulating ERK/p-ERK Expression in Rats.Chinese journal of integrative medicine · 2025Article
- Chemical Characterization and Antifungal Activity of Blue Tansy (Antibiotics (Basel, Switzerland) · 2023Article
- Modulation of Cell Death Pathways for Cellular Protection and Anti-Tumoral Activity: The Role ofInternational journal of molecular sciences · 2023Review
- The Prevention Role of Theaflavin-3,3'-digallate in Angiotensin II Induced Pathological Cardiac Hypertrophy via CaN-NFAT Signal Pathway.Nutrients · 2022Article
- Neuroprotective Effect of Luteolin-7-O-Glucoside against 6-OHDA-Induced Damage in Undifferentiated and RA-Differentiated SH-SY5Y Cells.International journal of molecular sciences · 2022Article
- Current Updates on Potential Role of Flavonoids in Hypoxia/Reoxygenation Cardiac Injury Model.Cardiovascular toxicology · 2021Review
- Function and Mechanism of Trimetazidine in Myocardial Infarction-Induced Myocardial Energy Metabolism Disorder Through the SIRT1-AMPK Pathway.Frontiers in physiology · 2021Article
- Protective Effects of Polyphenols against Ischemia/Reperfusion Injury.Molecules (Basel, Switzerland) · 2020Review
- Article
- Curcumin attenuates hypoxia/reoxygenation‑induced myocardial injury.Molecular medicine reports · 2019Article
Corrections and comments
- Retraction · 2025-06-10Author Unresponsive · Concerns/Issues about Data · Duplication of Data · Euphemisms for Duplication · Euphemisms for Plagiarism · Investigation by Journal/Publisher · Investigation by Third Party · · See also: https://pubpeer.com/publications/0EBA396EC12A8F5F2025E1BDF84735
- Retracted
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myocardial hypertrophy is often associated with myocardial infarction. Luteolin-7-O-glucoside (LUTG) has the prosperity of preventing cardiomyocyte injury. The current study aimed to explore the potential protective effect of LUTG and its relevant mechanisms in the heart. To establish the cardiac hypertrophy model in vitro, Angiotensin II (Ang II) was used to stimuli H9c2 cells in this study. The CCK‑8 assay showed that LUTG pretreatment improved cell viability of cardiomyocytes co‑treated with Ang II and ischemia/reperfusion. LUTG decreased the reactive oxygen species levels. Furthermore, it was demonstrated LUTG could reduce the release amount of lactate dehydrogenase and recover the catalase activity according to the flow cytometry analysis, and activity detection, respectively in Ang II‑H/R‑treated H9c2 cells. In addition, the flow cytometry analysis showed that the pretreatment of LUTG mitigated cell apoptosis induced by hypoxia/reoxygenation in the cardiac hypertrophy model. Meanwhile, reverse transcription‑quantitative polymerase chain reaction and western blot assays showed that the apoptosis‑related genes, including poly (ADP‑ribose) polymerase, Fas, Fasl and Caspase‑3 were downregulated at the transcriptional and translational levels. Notably, the protien expression of phosphorylated (p)‑extracellular signal‑regulated kinas (ERK) 1/2, p‑janus kinase and p‑P38 were reduced, while the expression of p‑ERK5 was elevated in the LUTG pretreatment groups compared with the hypoxia/reoxygenation treatment group. Based on these results, it was suggested that the anti‑apoptosis effect of LUTG may be associated with regulating the activation of mitogen‑activated protein kinases signaling pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.